EP Patent

EP3892280A3 — Sars-cov-2 infection biomarkers and uses thereof

Assigned to Cincinnati Childrens Hospital Medical Center · Expires 2022-01-12 · 4y expired

What this patent protects

Disclosed herein are methods that employ the use of one or more biomarkers for the treatment of SARS-CoV-2 infected individuals (COVID-19 patients). The methods may employ detection and measurement of one or more cytokines, the measurement of which may be used to treat COVID-19 p…

USPTO Abstract

Disclosed herein are methods that employ the use of one or more biomarkers for the treatment of SARS-CoV-2 infected individuals (COVID-19 patients). The methods may employ detection and measurement of one or more cytokines, the measurement of which may be used to treat COVID-19 patients with one or more immunomodulatory therapies.

Drugs covered by this patent

Patent Metadata

Patent number
EP3892280A3
Jurisdiction
EP
Classification
—
Expires
2022-01-12
Drug substance claim
No
Drug product claim
No
Assignee
Cincinnati Childrens Hospital Medical Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.